Literature DB >> 27062195

Prognostic role of the Bethesda System for conventional papillary thyroid carcinoma.

Hye Mi Gweon1,2, Hye Ryoung Koo2, Eun Ju Son3, Jeong-Ah Kim1, Ji Hyun Youk1, Soon Won Hong4, Beom Jin Lim4.   

Abstract

BACKGROUND: The purpose of this study was to investigate the role of the Bethesda System for Reporting Thyroid Cytopathology (BSRTC) as a prognostic marker in conventional papillary thyroid carcinoma (PTC).
METHODS: A total of 397 patients who underwent ultrasound-guided fine-needle aspiration biopsy (FNAB) and surgery for conventional PTCs were enrolled. The association between the Bethesda category and histopathologic result was evaluated.
RESULTS: Among the Bethesda categories, a significant difference was found in the presence of extrathyroidal extension (Bethesda category III, 3.2% [7 of 220]; category V, 19.1% [42 of 220]; and category VI, 77.7% [171 of 220]; p < .001) and lymph node metastasis (Bethesda category III, 3.8% [6 of 156]; category V, 16.7% [26 of 156]; and category VI, 79.5% [124 of 156]; p < .001). Multivariate analysis showed that the Bethesda category was independently predictive of extrathyroidal extension (p = .013) and lymph node metastasis (p = .035).
CONCLUSION: Conventional PTC with a higher Bethesda category at the time of cytology diagnosis would be poor prognosis.
© 2016 Wiley Periodicals, Inc. Head Neck 38: First-1514, 2016. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Bethesda System for Reporting Thyroid Cytopathology; fine-needle aspiration biopsy; papillary thyroid carcinoma; prognosis; thyroid

Mesh:

Year:  2016        PMID: 27062195     DOI: 10.1002/hed.24466

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Associations between Bethesda categories and tumor characteristics of conventional papillary thyroid carcinoma.

Authors:  Vivian Youngjean Park; Eun-Kyung Kim; Jin Young Kwak; Jung Hyun Yoon; Hee Jung Moon
Journal:  Ultrasonography       Date:  2017-11-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.